COVE STRATEGIES for THE MEDICINES COMPANY
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 2nd Quarter - Report (this page) | Jul 20, 2011 | $40,000 | Replaced |
| 2nd Quarter - Amendment | Jan 19, 2012 | $60,000 | Yes |
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Copyright/Patent/Trademark CPT
HR 1249, America Invests Act: issues relating to filing deadline under the Hatch-Waxman Act for patent term restorations. H. Amdt 499: Amendment clarifies the deadline for filing patent term extension applications covering drug products that must be approved by the FDA.
| Lobbyist | Covered position, as disclosed |
|---|---|
| FRANK SADLER | — |
| MATTHEW SCHLAPP | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.